Misfolded Proteins in Neurodegenerative Dementias: Molecular Mechanisms

키워드

참고문헌 (170)

1. Carrell RW, "Conformational disease", Lancet, 350, pp.134~138 (1997)
2. Dobson CM, "Protein misfolding, evolution and disease", Trends Biochem Sci, 24, pp.329~332 (1999)
3. Soto C, "Protein misfolding and disease; protein refolding and therapy", FEBS Lett, 498, pp.204~207 (2001)
4. Soto C, "Unfolding the role of protein misfolding in neurodegenerative diseases", Nat Rev Neurosci, 4, pp.49~60 (2003)
5. Serpell LC, "Molecular structure of a fibrillar Alzheimer’s A beta fragment", Biochemistry, 39, pp.13269~13275 (2000)
6. Serpell LC, "Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation", Proc Natl Acad Sci U S A, 97, pp.4897~4902 (2000)
7. Teplow DB, "Structural and kinetic features of amyloid beta-protein fibrillogenesis", Amyloid, 5, pp.121~142 (1998)
8. Tagliavini F, "Synthetic peptides homologous to prion protein residues 106-147 form amyloid-like fibrils in vitro", Proc Natl Acad Sci U S A, 90, pp.9678~9682 (1993)
9. Jarrett JT, "The C-terminus of the beta protein is critical in amyloidogenesis", Ann N Y Acad Sci, 695, pp.144~148 (1993)
10. Scherzinger E, "Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington’s disease pathology", Proc Natl Acad Sci U S A, 96, pp.4604~4609 (1999)
11. Wood SJ, "Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson’s disease", J Biol Chem, 274, pp.19509~19512 (1999)
12. Thal DR, "Phases of A beta-deposition in the human brain and its relevance for the development of AD", Neurology, 58, pp.1791~1800 (2002)
13. Buckner RL, "Molecular, structural, and functional characterization of Alzheimer’s disease: evidence for a relationship between default activity, amyloid, and memory", J Neurosci, 25, pp.7709~7717 (2005)
14. Walker LC, "Amyloid by default", Nat Neurosci, 14, pp.669~670 (2011)
15. Braak H, "Neuropathological stageing of Alzheimer-related changes", Acta Neuropathol, 82, pp.239~259 (1991)
16. Braak H, "The pathological process underlying Alzheimer’s disease in individuals under thirty", Acta Neuropathol, 121, pp.171~181 (2011)
17. Zoghbi HY, "Glutamine repeats and neurodegeneration", Annu Rev Neurosci, 23, pp.217~247 (2000)
18. Braak H, "Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages)", J Neurol, 249(3), pp.1~5 (2002)
19. Braak H, "Staging of brain pathology related to sporadic Parkinson’s disease", Neurobiol Aging, 24, pp.197~211 (2006)
20. Halliday GM, "Human-based studies on alpha-synuclein deposition and relationship to Parkinson’s disease symptoms", Exp Neurol, 209, pp.12~21 (2008)
21. Gai WP, "Multiple-system atrophy: a new alpha-synuclein disease?", Lancet, 352, pp.547~548 (1998)
22. Forman MS, "Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs", Nat Med, 10, pp.1055~1063 (2004)
23. Neumann M, "TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions", J Neuropathol Exp Neurol, 66, pp.177~183 (2007)
24. Neumann M, "Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease", Acta Neuropathol, 118, pp.605~616 (2009)
25. Kamenetz F, "APP processing and synaptic function", Neuron, 37, pp.925~937 (2003)
26. Haass C, "Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide", Nat Rev Mol Cell Biol, 8, pp.101~112 (2007)
27. Gandy S, "Molecular and cellular basis for anti-amyloid therapy in Alzheimer disease", Alzheimer Dis Assoc Disord, 17, pp.259~266 (2003)
28. Selkoe D, "Alzheimer’s disease: molecular understanding predicts amyloid-based therapeutics", Annu Rev Pharmacol Toxicol, 43, pp.545~584 (2003)
29. Furukawa K, "Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain", J Neurochem, 67, pp.1882~1896 (1996)
30. Kanemitsu H, "Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form", Neurosci Lett, 350, pp.113~116 (2003)
31. Qiu WQ, "Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation", J Biol Chem, 273, pp.32730~32738 (1998)
32. Leissring MA, "Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death", Neuron, 40, pp.1087~1093 (2003)
33. Walsh DM, "A beta oligomers - a decade of discovery", J Neurochem, 101, pp.1172~1184 (2007)
34. Jellinger KA, "Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease", Acta Neuropathol, 115, pp.427~436 (2008)
35. Merdes AR, "Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies", Neurology, 60, pp.1586~1590 (2003)
36. Jellinger KA, "Significance of brain lesions in Parkinson disease dementia and Lewy body dementia", Front Neurol Neurosci, 24, pp.114~125 (2009)
37. Giaccone G, "Down patients: extracellular preamyloid deposits precede neuritic degeneration and senile plaques", Neurosci Lett, 97, pp.232~238 (1989)
38. Flament S, "Phosphorylation of Tau proteins: a major event during the process of neurofibrillary degeneration. A comparative study between Alzheimer’s disease and Down’s syndrome", Brain Res, 516, pp.15~19 (1990)
39. Cork LC, "Neuropathology of Down syndrome and Alzheimer disease", Am J Med Genet Suppl, 7, pp.282~286 (1990)
40. Ghetti B, "Gerstmann-Sträussler-Scheinker disease. II. Neurofibrillary tangles and plaques with PrP-amyloid coexist in an affected family", Neurology, 39, pp.1453~1461 (1989)
41. Tagliavini F, "A68 is a component of paired helical filaments of Gerstmann-Sträussler-Scheinker disease", Indiana kindred. Brain Res, 616, pp.325~329 (1993)
42. Hsiao K, "Mutant prion proteins in Gerstmann-Sträussler-Scheinker disease with neurofibrillary tangles", Nat Genet, 1, pp.68~71 (1992)
43. Iqbal K, "Tau pathology in Alzheimer disease and other tauopathies", Biochim Biophys Acta, 1739, pp.198~210 (2005)
44. Khlistunova I, "Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs", J Biol Chem, 281, pp.1205~1214 (2006)
45. Oddo S, "Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles", J Biol Chem, 281, pp.39413~39423 (2006)
46. Lee HG, "Tau phosphorylation in Alzheimer’s disease: pathogen or protector?", Trends Mol Med, 11, pp.164~169 (2005)
47. McKee AC, "Neuritic pathology and dementia in Alzheimer’s disease", Ann Neurol, 30, pp.156~165 (1991)
48. Arriagada PV, "Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease", Neurology, 42, pp.631~639 (1992)
49. Neve RL, "Alzheimer’s disease: a re-examination of the amyloid hypothesis", Trends Neurosci, 21, pp.15~19 (1998)
50. Paulus W, "Corticonigral degeneration with neuronal achromasia and basal neurofibrillary tangles", Acta Neuropathol, 81, pp.89~94 (1990)
51. Ksiezak-Reding H, "Ultrastructure and biochemical composition of paired helical filaments in corticobasal degeneration", Am J Pathol, 145, pp.1496~1508 (1994)
52. Mori H, "Corticobasal degeneration: a disease with widespread appearance of abnormal tau and neurofibrillary tangles, and its relation to progressive supranuclear palsy", Acta Neuropathol, 88, pp.113~121 (1994)
53. Wakabayashi K, "Corticobasal degeneration: etiopathological significance of the cytoskeletal alterations", Acta Neuropathol, 87, pp.545~553 (1994)
54. Bancher C, "Neurofibrillary tangles in Alzheimer’s disease and progressive supranuclear palsy: antigenic similarities and differences. Microtubule-associated protein tau antigenicity is prominent in all types of tangles", Acta Neuropathol, 74, pp.39~46 (1987)
55. Flament S, "Abnormal Tau proteins in progressive supranuclear palsy. Similarities and differences with the neurofibrillary degeneration of the Alzheimer type", Acta Neuropathol, 81, pp.591~596 (1991)
56. Schmidt ML, "Neurofibrillary tangles in progressive supranuclear palsy contain the same tau epitopes identified in Alzheimer’s disease PHFtau", J Neuropathol Exp Neurol, 55, pp.534~539 (1996)
57. Papp MI, "Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome)", J Neurol Sci, 94, pp.79~100 (1989)
58. Eidelberg D, "Adult onset Hallervorden-Spatz disease with neurofibrillary pathology. A discrete clinicopathological entity", Brain, 110(4), pp.993~1013 (1987)
59. Perry G, "Filaments of Pick’s bodies contain altered cytoskeletal elements", Am J Pathol, 127, pp.559~568 (1987)
60. Murayama S, "Immunocytochemical and ultrastructural studies of Pick’s disease", Ann Neurol, 27, pp.394~405 (1990)
61. Lieberman AP, "Cognitive, neuroimaging, and pathological studies in a patient with Pick’s disease", Ann Neurol, 43, pp.259~265 (1998)
62. Wilhelmsen KC, "Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22", Am J Hum Genet, 55, pp.1159~1165 (1994)
63. Foster NL, "Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference", Conference Participants. Ann Neurol, 41, pp.706~715 (1997)
64. Papp MI, "Accumulation of tubular structures in oligodendroglial and neuronal cells as the basic alteration in multiple system atrophy", J Neurol Sci, 107, pp.172~182 (1992)
65. Nishimura M, "Glial fibrillary tangles with straight tubules in the brains of patients with progress ive supranuclear palsy", Neurosci Lett, 143, pp.35~38 (1992)
66. Spillantini MG, "Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies", Brain Pathol, 8, pp.387~402 (1998)
67. Iwatsubo T, "Neuronal and glial tau-positive inclusions in diverse neurologic diseases share common phosphorylation characteristics", Acta Neuropathol, 88, pp.129~136 (1994)
68. Uéda K, "Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease", Proc Natl Acad Sci U S A, 90, pp.11282~11286 (1993)
69. Burré J, "Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro", Science, 329, pp.1663~1667 (2010)
70. Vekrellis K, "Neurobiology of alpha-synuclein", Mol Neurobiol, 30, pp.1~21 (2004)
71. Nalls MA, "Imputation of sequence variants for identification of genetic risks for Parkinson’s disease: a meta-analysis of genome-wide association studies", Lancet, 377, pp.641~649 (2011)
72. Hardy J, "The genetics of Parkinson’s syndromes: a critical review", Curr Opin Genet Dev, 19, pp.254~265 (2009)
73. Kahle PJ, "Alpha-Synucleinopathy models and human neuropathology: similarities and differences", Acta Neuropathol, 115, pp.87~95 (2008)
74. Neumann M, "Alpha-synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies", Acta Neuropathol, 100, pp.568~574 (2000)
75. Pollanen MS, "Pathology and biology of the Lewy body", J Neuropathol Exp Neurol, 52, pp.183~191 (1993)
76. Vekrellis K, "Pathological roles of α-synuclein in neurological disorders", Lancet Neurol, 10, pp.1015~1025 (2011)
77. Manson J, "The prion protein gene: a role in mouse embryogenesis?", Development, 115, pp.117~122 (1992)
78. Moser M, "Developmental expression of the prion protein gene in glial cells", Neuron, 14, pp.509~517 (1995)
79. Martins VR, "Cellular prion protein: on the road for functions", FEBS Lett, 512, pp.25~28 (2002)
80. Büeler H, "Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein", Nature, 356, pp.577~582 (1992)
81. Aguzzi A, "Prion diseases: Cannibals and garbage piles", Nature, 423, pp.127~129 (2003)
82. Aguzzi A, "Mammalian prion biology: one century of evolving concepts", Cell, 116, pp.313~327 (2004)
83. Prusiner SB, "Shattuck lecture--neurodegenerative diseases and prions", N Engl J Med, 344, pp.1516~1526 (2001)
84. Aguzzi A, "The transcellular spread of cytosolic amyloids, prions, and prionoids", Neuron, 64, pp.783~790 (2009)
85. Brown K, "The prion diseases", J Geriatr Psychiatry Neurol, 23, pp.277~298 (2010)
86. Walker LC, "Inducible proteopathies", Trends Neurosci, 29, pp.438~443 (2006)
87. Soto C, "Amyloids, prions and the inherent infec tious nature of misfolded protein aggregates", Trends Biochem Sci, 31, pp.150~155 (2006)
88. Frost B, "Prion-like mechanisms in neurodegenerative diseases", Nat Rev Neurosci, 11, pp.155~159 (2010)
89. Brundin P, "Prion-like transmission of protein aggregates in neurodegenerative diseases", Nat Rev Mol Cell Biol, 11, pp.301~307 (2010)
90. Goedert M, "The propagation of prion-like protein inclusions in neurodegenerative diseases", Trends Neurosci, 33, pp.317~325 (2010)
91. Richards RI, "Dynamic mutation: possible mechanisms and significance in human disease", Trends Biochem Sci, 22, pp.432~436 (1997)
92. Shao J, "Polyglutamine diseases: emerging concepts in pathogenesis and therapy", Hum Mol Genet, 16(2), pp.115~123 (2007)
93. Schaffar G, "Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation", Mol Cell, 15, pp.95~105 (2004)
94. Nagai Y, "A toxic monomeric conformer of the polyglutamine protein", Nat Struct Mol Biol, 14, pp.332~340 (2007)
95. Koide R, "Atrophy of the cerebellum and brainstem in dentatorubral pallidoluysian atrophy. Influence of CAG repeat size on MRI findings", Neurology, 49, pp.1604~1612 (1997)
96. Bauer P, "Trinucleotide repeat expansion in SCA17", TBP in white patients with Huntington’s disease-like phenotype, 2004, pp.41, 230~232
97. Schöls L, "Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis", Lancet Neurol, 3, pp.291~304 (2004)
98. Koide R, "Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA)", Nat Genet, 6, pp.9~13 (1994)
99. Nucifora FC, "Nuclear localization of a non-caspase truncation product of atrophin-1, with an expanded polyglutamine repeat, increases cellular toxicity", J Biol Chem, 278, pp.13047~13055 (2003)
100. Nakamura K, "SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein", Hum Mol Genet, 10, pp.1441~1448 (2001)
101. Ayala YM, "Structural determinants of the cellular localization and shuttling of TDP-43", J Cell Sci, 121, pp.3778~3785 (2008)
102. Seelaar H, "Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review", J Neurol Neurosurg Psychiatry, 82, pp.476~486 (2011)
103. Nakano I, "Frontotemporal lobar degeneration (FTLD) concept and classification update", Rinsho Shinkeigaku, 51, pp.844~847 (2011)
104. Geser F, "Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam", Acta Neuropathol, 115, pp.133~145 (2008)
105. Neumann M, "Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis", Science, 314, pp.130~133 (2006)
106. Brandmeir NJ, "Severe subcortical TDP-43 pathology in sporadic frontotemporal lobar degeneration with motor neuron disease", Acta Neuropathol, 115, pp.123~131 (2008)
107. Benajiba L, "TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration", Ann Neurol, 65, pp.470~473 (2009)
108. Cairns NJ, "TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions", Am J Pathol, 171, pp.227~240 (2007)
109. Neumann M, "TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations", J Neuropathol Exp Neurol, 66, pp.152~157 (2007)
110. DeJesus-Hernandez M, "Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS", Neuron, 72, pp.245~256 (2011)
111. Renton AE, "A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD", Neuron, 72, pp.257~268 (2011)
112. Crozat A, "Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma", Nature, 363, pp.640~644 (1993)
113. Vance C, "Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6", Science, 323, pp.1208~1211 (2009)
114. Kwiatkowski TJ, "Mutations in the FUS", TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis, 2009, pp.323, 1205~1208
115. Urwin H, "FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration", Acta Neuropathol, 120, pp.33~41 (2010)
116. Neumann M, "A new subtype of frontotemporal lobar degeneration with FUS pathology", Brain, 132, pp.2922~2931 (2009)
117. Seelaar H, "Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration", J Neurol, 257, pp.747~753 (2010)
118. Munoz DG, "FUS pathology in basophilic inclusion body disease", Acta Neuropathol, 118, pp.617~627 (2009)
119. Mackenzie IR, "TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia", Lancet Neurol, 9, pp.995~1007 (2010)
120. Oddo S, "Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease", Neurobiol Aging, 24, pp.1063~1070 (2003)
121. Oddo S, "Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction", Neuron, 39, pp.409~421 (2003)
122. Götz J, "Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils", Science, 293, pp.1491~1495 (2001)
123. Lewis J, "Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP", Science, 293, pp.1487~1491 (2001)
124. Roberson ED, "Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model", Science, 316, pp.750~754 (2007)
125. Rapoport M, "Tau is essential to beta -amyloid-induced neurotoxicity", Proc Natl Acad Sci U S A, 99, pp.6364~6369 (2002)
126. Townsend M, "Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway", J Biol Chem, 282, pp.33305~33312 (2007)
127. Magdesian MH, "Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt", beta-catenin signaling, 2008, pp.283, 9359~9368
128. Ishiguro K, "Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments", FEBS Lett, 325, pp.167~172 (1993)
129. Alvarez G, "Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration", FEBS Lett, 453, pp.260~264 (1999)
130. Masliah E, "beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer’s disease and Parkinson’s disease", Proc Natl Acad Sci U S A, 98, pp.12245~12250 (2001)
131. Mucke L, "High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation", J Neurosci, 20, pp.4050~4058 (2000)
132. Halliday G, "Further evidence for an association between a mutation in the APP gene and Lewy body formation", Neurosci Lett, 227, pp.49~52 (1997)
133. Laurén J, "Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers", Nature, 457, pp.1129~1132 (2009)
134. Chen S, "Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues", J Biol Chem, 285, pp.26377~2683 (2010)
135. Freir DB, "Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites", Nat Commun, 2, pp.336~ (2011)
136. Chen L, "Oligomeric alpha-synuclein inhibits tubulin polymerization", Biochem Biophys Res Commun, 356, pp.548~553 (2007)
137. Jensen PH, "Alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356", J Biol Chem, 274, pp.25481~25489 (1999)
138. Qureshi HY, "Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and alpha-synuclein mutations promote Tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitro", J Biol Chem, 286, pp.5055~5068 (2011)
139. Haggerty T, "Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson’s disease", Eur J Neurosci, 33, pp.1598~1610 (2011)
140. Zach S, "Signal transduction protein array analysis links LRRK2 to Ste20 kinases and PKC zeta that modulate neuronal plasticity", PLoS One, 5, pp.131~191 (2010)
141. Lin CH, "LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ß", J Neurosci, 30, pp.13138~13149 (2010)
142. Melrose HL, "Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice", Neurobiol Dis, 40, pp.503~517 (2010)
143. Ito D, "Conjoint pathologic cascades mediated by ALS", FTLD-U linked RNA-binding proteins TDP-43 and FUS, 2011, pp.77, 1636~1643
144. Conway KA, "Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy", Proc Natl Acad Sci U S A, 97, pp.571~576 (2000)
145. Trojanowski JQ, "Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia", Arch Neurol, 55, pp.151~152 (1998)
146. Michalik A, "Pathogenesis of polyglutamine disorders: aggregation revisited", Hum Mol Genet, 12(2), pp.173~186 (2003)
147. Saudou F, "Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions", Cell, 95, pp.55~66 (1998)
148. Sisodia SS, "Nuclear inclusions in glutamine repeat disorders: are they pernicious, coincidental, or beneficial?", Cell, 95, pp.1~4 (1998)
149. Koffie RM, "Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques", Proc Natl Acad Sci U S A, 106, pp.4012~4017 (2009)
150. Knowles RB, "Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer’s disease", Proc Natl Acad Sci U S A, 96, pp.5274~5279 (1999)
151. Shankar GM, "Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory", Nat Med, 14, pp.837~842 (2008)
152. Selkoe DJ., "Resolving controversies on the path to Alzheimer’s therapeutics", Nat Med, 17, pp.1060~1065 (2011)
153. Casanova MF, "Senile plaques exert no mass lesion effect on surrounding neurons", J Neurosci Methods, 110, pp.125~133 (2001)
154. Brown P, "Alzheimer’s disease and transmissible virus dementia (Creutzfeldt-Jakob disease)", Ann N Y Acad Sci, 396, pp.131~143 (1982)
155. Prusiner SB., "Some speculations about prions, amyloid, and Alzheimer’s disease", N Engl J Med, 310, pp.661~663 (1984)
156. Gajdusek DC, "Spontaneous generation of infectious nucleating amyloids in the transmissible and nontransmissible cerebral amyloidoses", Mol Neurobiol, 8, pp.1~13 (1994)
157. Eisele YS, "Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation", Proc Natl Acad Sci U S A, 106, pp.12926~12931 (2009)
158. Kane MD, "Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice", J Neurosci, 20, pp.3606~3611 (2000)
159. Walker LC, "Exogenous induction of cerebral beta-amyloidosis in betaAPP-transgenic mice", Peptides, 23, pp.1241~1247 (2002)
160. Liu L, "Trans-synaptic spread of tau pathology in vivo", PLoS One, 7, pp.31302~ (2012)
161. Braak H, "Alzheimer’s pathogenesis: is there neuron-to-neuron propagation?", Acta Neuropathol, 121, pp.589~595 (2011)
162. Blaizot X, "Correlations between visual recognition memory and neocortical and hippocampal glucose metabolism after bilateral rhinal cortex lesions in the baboon: implications for Alzheimer’s disease", J Neurosci, 22, pp.9166~9170 (2002)
163. Volpicelli-Daley LA, "Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death", Neuron, 72, pp.57~71 (2011)
164. Desplats P, "Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein", Proc Natl Acad Sci U S A, 106, pp.13010~13015 (2009)
165. Kordower JH, "Lewy body-like pathology in long-term embryonic nigral transplants in Par kinson’s disease", Nat Med, 14, pp.504~506 (2008)
166. Olanow CW, "Is Parkinson’s disease a prion disorder?", Proc Natl Acad Sci U S A, 106, pp.12571~12572 (2009)
167. Furukawa Y, "A seeding reaction recapitulates intracellular formation of Sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions", J Biol Chem, 286, pp.18664~18672 (2011)
168. Ren PH, "Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates", Nat Cell Biol, 11, pp.219~225 (2009)
169. Cohen FE, "Therapeutic approaches to protein-misfolding diseases", Nature, 426, pp.905~909 (2003)
170. Rochet JC, "Novel therapeutic strategies for the treatment of protein-misfolding diseases", Expert Rev Mol Med, 9, pp.1~34 (2007)

관련 논문AI추천